GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Fusion Antibodies PLC (LSE:FAB) » Definitions » Loans Receivable

Fusion Antibodies (LSE:FAB) Loans Receivable : £0.00 Mil (As of Sep. 2023)


View and export this data going back to 2017. Start your Free Trial

What is Fusion Antibodies Loans Receivable?

Fusion Antibodies's Loans Receivable for the quarter that ended in Sep. 2023 was £0.00 Mil.


Fusion Antibodies Loans Receivable Historical Data

The historical data trend for Fusion Antibodies's Loans Receivable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Fusion Antibodies Loans Receivable Chart

Fusion Antibodies Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Loans Receivable
Get a 7-Day Free Trial Premium Member Only - - - - -

Fusion Antibodies Semi-Annual Data
Mar15 Mar16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23
Loans Receivable Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Fusion Antibodies Loans Receivable Calculation

Loans Receivable are the funds that a company has lent but have not yet been repaid.


Fusion Antibodies Loans Receivable Related Terms

Thank you for viewing the detailed overview of Fusion Antibodies's Loans Receivable provided by GuruFocus.com. Please click on the following links to see related term pages.


Fusion Antibodies (LSE:FAB) Business Description

Traded in Other Exchanges
N/A
Address
1 Springbank Road, Springbank Industrial Estate, Dunmurry, Belfast, GBR, BT17 0QL
Fusion Antibodies PLC offers a range of antibody engineering services for all stages of therapeutic and diagnostic antibody development. It is engaged in the research, development, and manufacturing of recombinant proteins, particularly in the areas of cancer and infectious diseases. Its services include antibody sequencing, antibody humanization, stable cell line development, monoclonal antibody production, and transient protein expression. Geographically company generates the majority of its revenue from North America.

Fusion Antibodies (LSE:FAB) Headlines

From GuruFocus

626 Financial, LLC Buys 3, Sells 2 in 3rd Quarter

By GuruFocus Research GuruFocus Editor 10-21-2022